期刊
FUTURE MICROBIOLOGY
卷 3, 期 6, 页码 593-601出版社
FUTURE MEDICINE LTD
DOI: 10.2217/17460913.3.6.593
关键词
anidulafungin; echinocandin; invasive candidiasis
类别
资金
- Merck
- Pfizer
A third echinocandin, anidulafungin, has recently been approved for Candida infections in the non-neutropenic patient. In the EU it is indicated for Invasive candidiasis; in 2006 It was approved in the USA for candida esophagitis, candidemia, and two types of invasive infections, peritonitis and intra-abdominal abscesses, It is fungicidal against Candida species and fungistatic against Aspergillus species. In addition to its favorable tolerability in studies to date, it does not need adjustment for renal or hepatic insufficiency and has no known drug interactions. A steady state concentration can be achieved on day 2 following a loading dose of twice the maintenance concentration on day 1, and the drug is administered Intravenously once daily. Cross resistance with other classes of antifungals is not a concern as it possesses a unique mechanism of action.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据